#United States #Orlando #COPD #Altesa BioSciences #Vapendavir

Altesa BioSciences at the American Thoracic Society 2026 International Congress

On April 30, 2026, in Atlanta, Altesa BioSciences, a notable player in the pharmaceutical industry, announced its selection for an oral presentation at the prestigious American Thoracic Society (ATS) International Congress 2026. This conference will take place in Orlando, Florida, and marks a significant milestone in the company's quest to combat Chronic Obstructive Pulmonary Disease (COPD) and asthma exacerbations, conditions that affect millions worldwide.

The centerpiece of their presentation is an abstract titled 'Treatment with Vapendavir after Rhinovirus Challenge in COPD Protects Lung Function and Accelerates Virus Clearance and Symptom Resolution – Results from a Phase 2a randomized double-blind placebo-controlled trial.' This study represents a groundbreaking advancement, detailing the efficacy of Vapendavir, an investigational oral medication under development specifically for conditions triggered by rhinovirus, a leading cause of respiratory issues in COPD patients.

Impact of Vapendavir

Dr. Sebastian Johnston, a prominent figure in respiratory medicine from the National Heart and Lung Institute, will deliver the findings. The abstract sheds light on how Vapendavir not only alleviates lower respiratory symptoms but also enhances the quality of life and sustains lung function among patients. Such implications are of paramount importance, as they indicate a potential breakthrough in managing rhinovirus-induced exacerbations in COPD patients, a need that remains largely unmet in today's clinical landscape.

Dr. Katharine Knobil, Chief Medical Officer of Altesa and a veteran in the pharmaceutical sector, expressed optimism regarding these results. She highlighted that Vapendavir's ability to ameliorate symptoms and uphold lung function could serve as a pivotal step forward in the treatment of COPD, paving the way for larger clinical trials.

Future Directions: The CARDINAL Study

Building on the promising data, Altesa BioSciences is set to embark on a multicenter, multinational Phase 2b randomized trial named the CARDINAL Study. Slated to commence in the second quarter of 2026, this trial will recruit 900 COPD patients across the United States and the United Kingdom. The design seeks to simulate real-world medical practices by identifying and supporting those at highest risk for rhinovirus infections.

Participants will undergo meticulous monitoring, and upon confirming rhinovirus infection, they will be randomized to receive either Vapendavir or a placebo. The primary goal is to assess the improvement in respiratory symptoms through established patient-reported outcomes, with secondary outcomes focused on health resources, quality of life, and lung function metrics after treatment.

About Altesa BioSciences

Altesa BioSciences is committed to transforming healthcare for individuals grappling with chronic lung diseases, epitomized by their focus on viral respiratory infections as a leading cause of exacerbations. The company, bolstered by their recent oversubscribed $75 million Series B financing, aims to push Vapendavir towards regulatory approval, potentially altering the landscape of COPD treatment.

As they prepare for their presentation in Orlando, the anticipation builds not just for the data they will share but for the lives that could be fundamentally improved by their innovations in respiratory healthcare.